MX2021005236A - Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. - Google Patents

Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.

Info

Publication number
MX2021005236A
MX2021005236A MX2021005236A MX2021005236A MX2021005236A MX 2021005236 A MX2021005236 A MX 2021005236A MX 2021005236 A MX2021005236 A MX 2021005236A MX 2021005236 A MX2021005236 A MX 2021005236A MX 2021005236 A MX2021005236 A MX 2021005236A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
tigit antibody
dosing regimen
antibody
Prior art date
Application number
MX2021005236A
Other languages
English (en)
Spanish (es)
Inventor
Jane Anne Healy
Mingmei Cai
Elliot K Chartash
Mallika Lala
Tommy Ruosi Li
Kapil Mayawala
Raluca Andreia Predoiu
Sybil M G Williams
Zhen Zeng
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2021005236A publication Critical patent/MX2021005236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2021005236A 2018-11-05 2019-11-04 Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. MX2021005236A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755805P 2018-11-05 2018-11-05
PCT/US2019/059581 WO2020096915A1 (en) 2018-11-05 2019-11-04 Dosing regimen of anti-tigit antibody for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021005236A true MX2021005236A (es) 2021-06-18

Family

ID=70611082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005236A MX2021005236A (es) 2018-11-05 2019-11-04 Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.

Country Status (10)

Country Link
US (1) US20210403557A1 (https=)
EP (1) EP3877418A4 (https=)
JP (2) JP2022512851A (https=)
KR (1) KR20210091209A (https=)
CN (1) CN113302204A (https=)
AU (1) AU2019375409A1 (https=)
BR (1) BR112021008582A8 (https=)
CA (1) CA3118964A1 (https=)
MX (1) MX2021005236A (https=)
WO (1) WO2020096915A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
KR20230024368A (ko) * 2020-06-18 2023-02-20 제넨테크, 인크. 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
WO2022063100A1 (zh) * 2020-09-22 2022-03-31 南京圣和药业股份有限公司 抗tigit抗体及双抗体和它们的应用
WO2023018677A1 (en) * 2021-08-10 2023-02-16 Merck Sharp & Dohme Llc A therapeutic combination comprising a t1git antagonist, a pd-1 antagonist, and a chemotherapeutic agent(s)
US20250064794A1 (en) * 2021-08-10 2025-02-27 Eisai R&D Management Co., Ltd. A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025128499A1 (en) * 2023-12-12 2025-06-19 Merck Sharp & Dohme Llc Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN118671353A (zh) * 2024-05-30 2024-09-20 中国人民解放军总医院第一医学中心 用于ais诊断的生物标志物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507482UA (en) * 2013-03-15 2015-10-29 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
MD4733C1 (ro) * 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
PE20181046A1 (es) * 2015-09-25 2018-07-03 Genentech Inc Anticuerpos anti-tigit y metodos de uso
CA3025391A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
ES2965352T3 (es) * 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY

Also Published As

Publication number Publication date
WO2020096915A1 (en) 2020-05-14
EP3877418A1 (en) 2021-09-15
AU2019375409A1 (en) 2021-05-27
JP2025004212A (ja) 2025-01-14
US20210403557A1 (en) 2021-12-30
BR112021008582A2 (pt) 2021-08-10
EP3877418A4 (en) 2022-08-17
CN113302204A (zh) 2021-08-24
BR112021008582A8 (pt) 2023-02-07
KR20210091209A (ko) 2021-07-21
CA3118964A1 (en) 2020-05-14
JP2022512851A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
MX2021005236A (es) Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
PH12019500270A1 (en) Combination therapy for cancer
CY1123993T1 (el) Μεθοδος αγωγης καρκινου χρησιμοποιωντας αναστολεα σημειων ελεγχου ανοσιακου• αντισωμα που δεσμευεται σε υποδοχεα προγραμματισμενου θανατου-1 (pd-1) ή προσδετη 1 προγραμματισμενου θανατου (pd-l1)
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MY195474A (en) Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
MY205639A (en) Fgfr/pd-1 combination therapy for the treatment of cancer
MY208638A (en) Anti-steap1 antigen-binding protein
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
MX2021006786A (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2019002562A (es) Métodos para tratar cáncer que expresa la proteína del ligando 1 de muerte celular programada (pd-l1).
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
MX2021013467A (es) Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
EA201890278A1 (ru) Антитела к pd-l1
ZA201907135B (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
WO2018102589A3 (en) Anti-hrs antibodies and combination therapies for treating cancers
MX2020012755A (es) Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
MX2020012613A (es) Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2020009743A (es) Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)